This site uses cookies to provide a better browsing experience. More information can be found on our Privacy Policy page.

NodThera has changed its name to Rezera and announced a Phase 3 development program. Read Press Release

publications & posters

Check out our scientific presentations to learn more about our ongoing drug development programs.

Oral NLRP3 inhibitor ruvonoflast provides rapid, robust and reversible inflammation reduction in people with residual inflammatory risk of ASCVD

Ray, et al., Annual Meeting of the European Atherosclerosis Society (EAS)

Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk

Ray, et al., Journal of the American College of Cardiology

CNS-targeted NLRP3 Inhibition by NT-0527 confers therapeutic advantage in a CAPS mouse model

Koller, et al., Journal of Neuroinflammation

Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1

Digby, et al., ACS Chemical Neuroscience

Quelling the fire within: inhibiting the NLRP3 inflammasome to treat chronic inflammation in multiple diseases

NodThera, Nature Biopharma Dealmakers

Evaluating the in vivo efficacy of NLRP3 inhibitor NT-0249 in preclinical models of chronic joint pain

Thornton, et al., Society for Neuroscience Annual Meeting | San Diego, CA

See Our Development Pipeline